Navigation Links
Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
Date:5/6/2013

CARLSBAD, Calif., May 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC).  HCC is a tumor of the liver and is one of the most common cancers worldwide with at least one million new cases diagnosed each year.  ISIS-STAT3Rx is an antisense drug discovered by Isis and being developed to treat patients with cancers with a strong link to STAT3, such as HCC.  Isis licensed ISIS-STAT3Rx to AstraZeneca as part of a strategic alliance in cancer. AstraZeneca is conducting this newly initiated study in patients with HCC.

"We are pleased to be working with AstraZeneca on the development of ISIS-STAT3Rx.  AstraZeneca's considerable resources, expertise and development capabilities to develop anti-cancer drugs strengthen substantially our ability to broadly evaluate ISIS-STAT3Rx across a range of cancer types. Given the role of STAT3 in the growth and survival of tumors, we believe that ISIS-STAT3Rx could be beneficial in the treatment of many different types of cancers.  As such, together with AstraZeneca, we have designed a broad development program to explore the effects of ISIS-STAT3Rx in a number of different cancers," said B. Lynne Parshall , chief operating officer at Isis.  "Our early work showed that ISIS-STAT3Rx treatment resulted in clear responses in patients with advanced cancer who were refractory to prior chemotherapy treatment, with an acceptable safety profile.  The new study builds on this early work and expands our evaluation of ISIS-STAT3Rx into liver cancer where STAT3 inhibition could also provide therapeutic benefit."


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... and ST. LOUIS , May ... pressure or high cholesterol may achieve better health outcomes ... according to early results of a unique program conducted ... ESRX ). "Pharmacists are one of the ... interactions with our members presents enormous opportunities to positively ...
(Date:5/5/2015)... 2015 Big Market Research presents a detailed ... Europe , ( France , Germany ... , UK) and Japan . Current scientific views ... provides the 5-year test volume and sales forecasts by country for ... Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed ...
(Date:5/5/2015)... 2015 E-QURE (Electric Quick Ulcer ... premier provider of innovative medical devices in the field ... to shareholders and the investment community, covering 2014 - ... the proprietary Bioelectrical Signal Therapy™ (BST) Device for advanced ... as well as its plans for commercialization and sale ...
Breaking Medicine Technology:SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 42015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 2E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 4E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 5
(Date:5/5/2015)... May 05, 2015 The global lab ... 2020 from $3,474.2 Million in 2014, at an estimated ... segments the lab automation market on the basis of ... and region. On the basis of application, Lab Automation ... solutions, and proteomics solutions. Drug discovery is a major ...
(Date:5/5/2015)... May 05, 2015 Viverae®, a ... Bard Inc., a leading multinational developer, manufacturer and ... fields of vascular, urology, oncology and surgical specialty ... Award. The Vanguard Award recognizes outstanding achievement ... programs among Viverae’s significant client base. , Viverae ...
(Date:5/5/2015)... Dr. Patricia George knows all too well the ... pulmonary hypertension specialist at the University of Pittsburgh Medical ... an initial idea entered her mind for Team PHenomenal ... at the 2010 PHA International Conference,” George recalled. “The ... recalling their climb up Mt. Kilimanjaro and I remember ...
(Date:5/5/2015)... In a April 25, 2015, report published in ... Missouri State Highway Patrol (MSHP) announced that Indiana led the ... the second year in a row. , The MSHP, ... incidents in 2014 alone, around 15% of the national total. ... US Population calls Indiana home, according to the report. , ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Platform that enables businesses to deploy Mobile Engagement Campaigns ... Constant Contact . ProTexting clients can now leverage the ... reach by collecting and syncing subscribers’ e-mail addresses into ... says “We have recognized that the growing trend of ...
Breaking Medicine News(10 mins):Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3
... occurs in sperm could be the key to a new ... an ion channel protein that controls the flow of calcium ... swim, so a drug designed to block the channel would ... in this week's Nature by Dr Arnold Clapham, from the ...
... cell disease is an inherited blood disorder that affects ... red blood cells that contain an abnormal type of ... have difficulty passing through small blood vessels. When sickle-shaped ... is often pain severe enough to require hospital admission. ...
... intestine could hold the key to permanent weight loss. ... is produced in the small intestine in response to ... development of better treatments for eating disorders and obesity. ... and profoundly different from those of traditional appetite suppressants. ...
... that tend to be slightly elevated but still considered ... for suffering from heart disease. Blood pressure readings are ... first number in a blood pressure measurement, represents the ... the diastolic value, represents the pressure when the heart ...
... be mindful of the possible interaction between oral ... Centers for Disease Control and Prevention (CDC) to ... and anti-infective medications, such as Cipro, doxycycline, and ... have been exposed to anthrax spores.// Many antibiotics ...
... significant breakthrough, a team of scientists have successfully transplanted ... diseased one, bringing light to the people who nearly ... about stem cells, in all 33 patients who suffered ... drug and auto-immune diseases causing damage to the part ...
Cached Medicine News:
For the quantitative determination of total protein in serum. Linearity: 1-15 g/dl....
... the quantitative determination of urea ... lag phase of less than ... phase of at least 240 ... 100 mg/dL (35.6 mmol/L urea) ...
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
Medicine Products: